Hydroxyurea is a medication that alters dna synthesis in rapidly dividing cells. It is used primarily to treat certain cancers and chronic myeloid leukemia by reducing abnormal blood cell production. The drug works by inhibiting the enzyme ribonucleotide reductase which is required for dna precursor formation. This inhibition leads to decreased dna replication in cells that divide quickly causing them to stop dividing and undergo programmed cell death. By lowering the uncontrolled proliferation of malignant cells the therapy helps control disease progression and can relieve symptoms associated with the malignancy. Overall the active ingredient Hydroxyurea produces its therapeutic effect through suppression of dna synthesis which disrupts the life cycle of malignant cells and allows normal hematologic balance to be restored.

Hydroxyurea is an antimetabolite drug used primarily to reduce painful crises in sickle cell disease. It increases the production of fetal hemoglobin by inhibiting ribonucleotide reductase in erythroid cells. The elevated fetal hemoglobin reduces the tendency of sickle hemoglobin to polymerize. This effect improves oxygen delivery and lessens sickling of red blood cells. Hydroxyurea also acts as a cytotoxic agent by depleting nucleotide pools and inducing dna damage in rapidly dividing cells. Its antineoplastic use exploits this mechanism to treat certain leukemias and solid tumors. Pharmacologically the drug is absorbed orally and metabolized primarily in the liver. The therapeutic benefit arises from sustained elevation of hemoglobin f and decreased sickle cell hemolysis.

Headache is frequently reported after medication use. Nausea often occurs when the drug irritates the stomach lining. Some individuals experience drowsiness that may affect daily activities. A mild rash can develop as a skin reaction. Dizziness may appear, especially when standing up quickly. Changes in taste perception are occasionally noted. Fatigue can be observed during the early stages of treatment. Occasional fluctuations in blood pressure have been recorded in clinical studies.

Many people experience mild headache and muscle aches after vaccination. Redness or swelling at the injection site is frequently reported. Low grade fever can occur but usually resolves within a day. Nausea and loss of appetite may be observed in some individuals. Dizziness and occasional fainting are noted during blood draws. Skin rash or itching can develop as a localized reaction. Shortness of breath and chills are sometimes recorded but tend to be brief. These effects are generally self limited and not indicative of serious complications.